Amir Mehdizadeh, Morteza Bonyadi, Masoud Darabi, Reza Rahbarghazi, Soheila Montazersaheb, Kobra Velaei, Maghsood Shaaker, Mohammad-Hossein Somi*
|
Tatiana Matvienko, Viktoriya Sokolova, Svitlana Prylutska, Yuliia Harahuts, Nataliya Kutsevol, Viktor Kostjukov, Maxim Evstigneev*  , Yuriy Prylutskyy*, Matthias Epple, Uwe Ritter
It was found that the Dextran-PNIPAM+Dox nanofluid in contrast to Dox alone showed higher toxicity towards HeLa cells, whereas the SWCNT+Dox and GO+Dox nanofluids protected cells from Dox.
|
Forough Alemi , Masomeh Maleki, Mostafa Mir, Abbas Ebrahimi-Kalan, Mojtaba Zarei, Bahman Yousefi* , Nadereh Rashtchizadeh*
In this work, a graphene oxide-based nanoformulation was designed to deliver a high concentration of doxorubicin to osteosarcoma cancer cells. This nanoformulation showed a better release profile in an acidic condition of tumor site, and higher cytotoxicity and apoptosis rate in comparison to free doxorubicin, which suggests, it is a potential platform for targeted therapy of osteosarcoma.
|
Mina Yousefnezhad, Soodabeh Davaran* , Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).
|